bluebird bio Inc (NAS:BLUE)
$ 0.405 0.0272 (7.2%) Market Cap: 78.75 Mil Enterprise Value: 376.50 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 31/100

bluebird bio Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 10, 2021 / 02:15PM GMT
Release Date Price: $11.57 (-1.76%)
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

Good morning, everybody. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Very pleased to have bluebird with us for the next session.

Quickly before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/research disclosures.

And with that, I'm going to turn it over to Andrew to make some opening comments. And then we can get right into Q&A.

Andrew Obenshain
bluebird bio, Inc. - President of Severe Genetic Diseases

Hi, everyone. So for those of you who are used to see Nick Leschly as the CEO of bluebird, I'm Andrew Obenshain and I'm currently the President of the Rare Disease Division. And come our split in October, I will become the CEO of bluebird, so a new face for many of you I'm sure.

I am joined

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot